These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 18852147

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X, Lu M, Li C, Deng S, Li M.
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [Abstract] [Full Text] [Related]

  • 3. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
    Miyamoto S, Yagi H, Yotsumoto F, Horiuchi S, Yoshizato T, Kawarabayashi T, Kuroki M, Mekada E.
    Anticancer Res; 2007 Jul; 27(6A):3713-21. PubMed ID: 17970033
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
    Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E.
    Cancer Res; 2004 Aug 15; 64(16):5720-7. PubMed ID: 15313912
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M.
    Oncol Rep; 2003 Aug 15; 10(1):89-95. PubMed ID: 12469150
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S, Ohnishi Y, Kakudo K.
    Med Mol Morphol; 2012 Jun 15; 45(2):91-7. PubMed ID: 22718294
    [Abstract] [Full Text] [Related]

  • 10. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH, Deng S, Li M, Lu MS.
    Biochem Biophys Res Commun; 2012 Jun 15; 422(4):676-80. PubMed ID: 22609777
    [Abstract] [Full Text] [Related]

  • 11. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
    Wang F, Sloss C, Zhang X, Lee SW, Cusack JC.
    Cancer Res; 2007 Sep 15; 67(18):8486-93. PubMed ID: 17875687
    [Abstract] [Full Text] [Related]

  • 12. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH, Deng S, Li M, Lu MS.
    Tumour Biol; 2016 Apr 15; 37(4):5521-8. PubMed ID: 26572150
    [Abstract] [Full Text] [Related]

  • 13. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
    Tang XH, Lu MS, Deng S, Li M.
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr 25; 54(4):255-261. PubMed ID: 31006192
    [Abstract] [Full Text] [Related]

  • 14. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.
    Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW.
    PLoS One; 2011 Apr 25; 6(11):e27720. PubMed ID: 22110740
    [Abstract] [Full Text] [Related]

  • 15. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S, Drake AW, Tsuji I, Fan J.
    PLoS One; 2012 Apr 25; 7(12):e51964. PubMed ID: 23251664
    [Abstract] [Full Text] [Related]

  • 16. Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling.
    Cole CL, Rushton G, Jayson GC, Avizienyte E.
    J Biol Chem; 2014 Apr 11; 289(15):10488-10501. PubMed ID: 24563483
    [Abstract] [Full Text] [Related]

  • 17. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.
    Ota I, Higashiyama S, Masui T, Yane K, Hosoi H, Matsuura N.
    Oncol Rep; 2013 Oct 11; 30(4):1593-600. PubMed ID: 23917679
    [Abstract] [Full Text] [Related]

  • 18. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells.
    Narita T, Kawakami-Kimura N, Sato M, Matsuura N, Higashiyama S, Taniguchi N, Kannagi R.
    Oncology; 1996 Oct 11; 53(5):374-81. PubMed ID: 8784471
    [Abstract] [Full Text] [Related]

  • 19. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
    Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
    Clin Cancer Res; 2011 Jun 01; 17(11):3619-30. PubMed ID: 21482691
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model.
    Li Z, Yan H, Yuan J, Cao L, Lin A, Dai H, Ni Z, Qian J, Fang W.
    Clin Exp Nephrol; 2018 Apr 01; 22(2):257-265. PubMed ID: 28710535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.